Recent development of antibody drug conjugate

Abstract

An antibody-drug conjugate (ADC) is a new way of formulating antibody drugs that achieves specific binding to the antigen and can deliver the drug to the disease site. The recent advances in antibody specificity, linker technology, and drug optimization have made it possible for ADCs to enter clinical trials. In the present review, I would like to make a summary of ADCs that have been launched or are currently being developed.